11-acetyl-8-carbamoyloxymethyl-4-formyl-6-methoxy-14-oxa-1-11-diazatetracyclo(7.4.1.0.0)tetradeca-2-4-6-trien-9-yl-acetate and Carcinoma--Lewis-Lung
11-acetyl-8-carbamoyloxymethyl-4-formyl-6-methoxy-14-oxa-1-11-diazatetracyclo(7.4.1.0.0)tetradeca-2-4-6-trien-9-yl-acetate has been researched along with Carcinoma--Lewis-Lung* in 1 studies
Other Studies
1 other study(ies) available for 11-acetyl-8-carbamoyloxymethyl-4-formyl-6-methoxy-14-oxa-1-11-diazatetracyclo(7.4.1.0.0)tetradeca-2-4-6-trien-9-yl-acetate and Carcinoma--Lewis-Lung
| Article | Year |
|---|---|
Effects of FK317, a novel anti-cancer agent, on survival of mice bearing B16BL6 melanoma and Lewis lung carcinoma.
The effects of FK317 (11-acetyl-8-carbamoyloxymethyl-4-formyl-6-methoxy-14- oxa-1,11-diazatraacylo[7.4.1.0(2.7).0(10.2)]-tetradeca-2,4,6-trien-9-yl acetate), a novel anti-cancer agent, and mitomycin C (MMC) on survival time of mice bearing B16BL6 melanoma and Lewis lung carcinoma (LLC), induced by intravenous inoculation of the tumor, were investigated. Treatment with FK317 resulted in a significant prolongation of survival time in both tumor models. Four of ten mice bearing B16BL6 were disease-free following FK317 treatment. In contrast, MMC was not effective in prolonging survival time. Overall, this study demonstrated that FK317 shows more potent survival extension in mice bearing B16BL6 and LLC than MMC, suggesting that FK317 may have therapeutic utility for cancer chemotherapy. Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Drug Evaluation; Female; Melanoma, Experimental; Mice; Mice, Inbred Strains; Mitomycin; Oxazines; Survival Analysis | 2002 |